Resource Logo
Reuters New Media

Patient Makes Anti-HIV Immunity Cells in Enzo Trail




 

FARMINGDALE, N.Y. (Reuters) - Biotech company Enzo Biochem Inc. (NYSE:ENZ - news) said on Monday a patient participating in a Phase I study produced new immunity cells to combat the virus that causes AIDS web-.

The tests show that after nine-and-one-half months, Enzo- engineered cells have successfully engrafted in the patient's bone marrow and were spawning new cells designed to fight HIV.

The company said it is preparing for a Phase II trial of the HGTV-43 medicine product and has already begun negotiating with several hospitals at which broader studies would be conducted.

Enzo is compiling and analyzing data from the remaining five patients in the trial, and said that the data is highly encouraging, though limited and must await further study.



 


Copyright © 2000 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in October 2, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.